We further demonstrate that TβRII-ED-Fc is a versatile ligand-trapping module that, when combined with a specific targeting moiety, can lead to powerful anticancer biotherapeutics targeted to and retained at the tumor site, by efficiently neutralizing the tumor-promoting activities of TGF-β in vivo. Here, TGFBR2 is linked to neoplasm.